Key facts
- This page summarizes Jay B. Lichter's Form 4 filing for Janux Therapeutics, Inc. (JANX).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 24 Oct 2024, 16:15.
Jay B. Lichter - 13 Sep 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- JANX
- Reported as of
- 13 Sep 2024
- Net transaction value
- -$112,133
- SEC form
- 4
- Accepted by SEC
- 24 Oct 2024, 16:15:07 UTC
- Prior SEC filing
- 28 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jay B. Lichter
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jay B. Lichter filed Form 4 for Janux Therapeutics, Inc. (JANX) on 24 Oct 2024.
Change
- Previous filing in this sequence was filed on 28 Jun 2024.
- Current net transaction value: -$112,133.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JANX
transaction
Common Stock
Options Exercise
- Transaction value
- $31,756
- Shares
- +1,868
- Change %
- +27%
- Price
- $17.00
- Shares after
- 8,868
- Date
- 13 Sep 2024
- Ownership
- Direct
JANX
transaction
Common Stock
Options Exercise
- Transaction value
- $8,348
- Shares
- +778
- Change %
- +8.8%
- Price
- $10.73
- Shares after
- 9,646
- Date
- 13 Sep 2024
- Ownership
- Direct
JANX
transaction
Common Stock
Options Exercise
- Transaction value
- $10,285
- Shares
- +778
- Change %
- +8.1%
- Price
- $13.22
- Shares after
- 10,424
- Date
- 13 Sep 2024
- Ownership
- Direct
JANX
transaction
Common Stock
Options Exercise
- Transaction value
- $15,562
- Shares
- +391
- Change %
- +3.8%
- Price
- $39.80
- Shares after
- 10,815
- Date
- 13 Sep 2024
- Ownership
- Direct
JANX
transaction
Common Stock
Sale
- Transaction value
- $178,084
- Shares
- -3,815
- Change %
- -35%
- Price
- $46.68
- Shares after
- 7,000
- Date
- 13 Sep 2024
- Ownership
- Direct
JANX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,959,175
- Date
- 13 Sep 2024
- Ownership
- By Avalon Ventures XI, L.P.
- Footnotes
- F1
JANX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 573,227
- Date
- 13 Sep 2024
- Ownership
- By Avalon BioVentures I, LP
- Footnotes
- F2
JANX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,021,414
- Date
- 13 Sep 2024
- Ownership
- By Avalon BioVentures SPV I, L.P.
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JANX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,868
- Change %
- -6.4%
- Price
- $0.000000
- Shares after
- 27,138
- Date
- 13 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,868
- Exercise price
- $17.00
- Footnotes
- F4
JANX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -778
- Change %
- -6.4%
- Price
- $0.000000
- Shares after
- 11,308
- Date
- 13 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 778
- Exercise price
- $10.73
- Footnotes
- F4
JANX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -778
- Change %
- -6.4%
- Price
- $0.000000
- Shares after
- 11,308
- Date
- 13 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 778
- Exercise price
- $13.22
- Footnotes
- F4
JANX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -391
- Change %
- -4.8%
- Price
- $0.000000
- Shares after
- 7,682
- Date
- 13 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 391
- Exercise price
- $39.80
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jay B. Lichter is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Footnote F2
The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Footnote F3
The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Footnote F4
Immediately exercisable.
SEC remarks
The number of securities reported in Column 5 of Table I and Column 9 of Table II represent the number of securities beneficially owned immediately following the transactions reported herein and do not reflect transactions that occurred on dates subsequent to the transactions reported herein. Form 4s filed by the reporting person on September 30, 2024 and October 18, 2024 are deemed amended hereby to give effect to the transactions effected on September 13, 2024 reported herein.